JP7114604B2 - 脆弱ｘ症候群の治療のためのプリドピジンの使用 - Google Patents

脆弱ｘ症候群の治療のためのプリドピジンの使用 Download PDF

Info

Publication number
JP7114604B2
JP7114604B2 JP2019539958A JP2019539958A JP7114604B2 JP 7114604 B2 JP7114604 B2 JP 7114604B2 JP 2019539958 A JP2019539958 A JP 2019539958A JP 2019539958 A JP2019539958 A JP 2019539958A JP 7114604 B2 JP7114604 B2 JP 7114604B2
Authority
JP
Japan
Prior art keywords
pridopidine
fxs
subject
use according
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019539958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514313A (ja
JP2020514313A5 (enExample
Inventor
ヘイデン、マイケル
プーラディ、マムード・アブドルホセイン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Original Assignee
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore filed Critical National University of Singapore
Publication of JP2020514313A publication Critical patent/JP2020514313A/ja
Publication of JP2020514313A5 publication Critical patent/JP2020514313A5/ja
Application granted granted Critical
Publication of JP7114604B2 publication Critical patent/JP7114604B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2019539958A 2017-01-20 2018-01-18 脆弱ｘ症候群の治療のためのプリドピジンの使用 Active JP7114604B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448595P 2017-01-20 2017-01-20
US62/448,595 2017-01-20
PCT/US2018/014169 WO2018136600A1 (en) 2017-01-20 2018-01-18 Use of pridopidine for the treatment of fragile x syndrome

Publications (3)

Publication Number Publication Date
JP2020514313A JP2020514313A (ja) 2020-05-21
JP2020514313A5 JP2020514313A5 (enExample) 2021-03-04
JP7114604B2 true JP7114604B2 (ja) 2022-08-08

Family

ID=62908348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019539958A Active JP7114604B2 (ja) 2017-01-20 2018-01-18 脆弱ｘ症候群の治療のためのプリドピジンの使用

Country Status (13)

Country Link
US (2) US11234973B2 (enExample)
EP (1) EP3570940B1 (enExample)
JP (1) JP7114604B2 (enExample)
CN (1) CN110505902B (enExample)
AU (1) AU2018210145B2 (enExample)
BR (1) BR112019015000A2 (enExample)
CA (1) CA3050700C (enExample)
DK (1) DK3570940T3 (enExample)
ES (1) ES2972205T3 (enExample)
HU (1) HUE068300T2 (enExample)
IL (1) IL268125B2 (enExample)
PL (1) PL3570940T3 (enExample)
WO (1) WO2018136600A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011298382A1 (en) 2010-09-03 2013-05-02 Teva Pharmaceuticals International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
EP4088721B1 (en) * 2020-01-08 2025-09-17 Neuroventi Composition for treating fragile x syndrome or related developmental disorders, comprising lisuride compound as active ingredient
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508744A (ja) 2011-01-27 2014-04-10 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
WO2016138130A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
DK2146961T3 (da) 2007-04-12 2014-04-28 Ivax Int Gmbh N-oxid- og/eller di-N-oxidderivater af dopaminreceptorstabilisatorer/modulatorer udvisende forbedrede cardiovaskulære bivirkningsprofiler
WO2008133884A2 (en) 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
AU2011298382A1 (en) 2010-09-03 2013-05-02 Teva Pharmaceuticals International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
KR20140075703A (ko) 2011-09-07 2014-06-19 아이백스 인터내셔널 게엠베하 프리도피딘 하이드로클로라이드의 다형 형태
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 併用療法のための医薬組成物
HK1211483A1 (en) * 2012-09-27 2016-05-27 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
KR102316933B1 (ko) 2013-06-21 2021-10-26 프리레니아 뉴로테라퓨틱스 엘티디. 헌팅턴병 치료를 위한 프리도피딘의 용도
DK3096759T3 (da) 2014-01-22 2022-05-09 Prilenia Neurotherapeutics Ltd Pridopidinformuleringer med modificeret frigivelse
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
JP2018505147A (ja) 2014-12-22 2018-02-22 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジンのｌ−酒石酸塩
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508744A (ja) 2011-01-27 2014-04-10 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロピル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
WO2016138130A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Biochemical Pharmacology，Vol.81，2011年，p.1078-1086
Cogram et al ，Sigma-1 Receptor Agonists as Potential Treatment Options for Autism Spectrum Disorders: Pre-clinical Studies with ANAVEX 2-73 in a Fragile X Model'，Gordon Research Conference for Fragile X and Autism-Related Disorders，2016年06月，インターネット＜https://www.anavex.com//wp-content/uploads/Sigma-1-Receptor-Agonists-as-Potential-Treatment-Options.pdf＞
Current Genomics，2011年，Vol.12，p.216-224
European Journal of Pharmacology，Vol.644，2010年，p.88-95
Human Molecular Genetics，2016年，Vol.25, No.18，p.3975-3987
J Investig Med.，57(8)，2009年12月，p.830-836
J. Cell. Mol. Med.，2015年，Vol 19, No 11，pp. 2540-2548
Progress in Neuro-Psychopharmacology & Biological Psychiatry，Vol.28，2004年，p.677-685

Also Published As

Publication number Publication date
WO2018136600A1 (en) 2018-07-26
HUE068300T2 (hu) 2024-12-28
IL268125A (en) 2019-09-26
US11234973B2 (en) 2022-02-01
CA3050700C (en) 2023-10-03
PL3570940T3 (pl) 2024-06-17
ES2972205T3 (es) 2024-06-11
BR112019015000A2 (pt) 2020-04-07
IL268125B2 (en) 2023-04-01
JP2020514313A (ja) 2020-05-21
IL268125B (en) 2022-12-01
US20190336488A1 (en) 2019-11-07
AU2018210145B2 (en) 2023-06-29
AU2018210145A1 (en) 2019-08-29
CN110505902B (zh) 2022-11-11
CN110505902A (zh) 2019-11-26
EP3570940A4 (en) 2020-10-28
DK3570940T3 (da) 2024-02-19
EP3570940A1 (en) 2019-11-27
CA3050700A1 (en) 2018-07-26
EP3570940B1 (en) 2023-12-13
US20220202798A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
JP7114604B2 (ja) 脆弱ｘ症候群の治療のためのプリドピジンの使用
US11406625B2 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
CA3079259A1 (en) Ganaxolone for use in treating genetic epileptic disorders
JP2022062047A (ja) 不安症およびうつ病の治療のためのプリドピジンの使用
CN108420819A (zh) 用于治疗神经障碍的新组合物
KR20100024951A (ko) 세포를 자극하기 위한 방법 및 조성물
CN105744932A (zh) 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物
JP2020513005A (ja) Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
Sun et al. Development of novel treatments for amyotrophic lateral sclerosis
Lee et al. The effects of Korean Red Ginseng-derived components on oligodendrocyte lineage cells: Distinct facilitatory roles of the non-saponin and saponin fractions, and Rb1, in proliferation, differentiation and myelination
JP2023545846A (ja) 不安及び抑うつを治療するためのプリドピジンまたはその類似体の使用
RS65530B1 (sr) Derivati karbamoil cikloheksana za lečenje poremećaja iz spektra autizma
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
van Dijk et al. Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions
TWI879755B (zh) 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途
Zare et al. Wake-Promoting agents; insights into clinical use and molecular perspectives
CN120346202A (zh) Ripk1抑制剂及其在治疗神经功能障碍中的用途
Lazowski An Investigation of Sleep Architecture and Consequent Cognitive Changes in Olanzapine Treated Patients with Depression
BR122025001464A2 (pt) Uso de pridopidina e, opcionalmente, de um segundo composto para o tratamento de esclerose lateral amiotrófica (ela) e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220330

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220727

R150 Certificate of patent or registration of utility model

Ref document number: 7114604

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250